drugset / Trial / NCT01015040

Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers

NCT01015040

Phase 1 Completed 24 enrolled Astellas Pharma Inc
RandomizedCrossoverOpen-label

Summary

The objective of the study is to compare the relative bioavailability and pharmacokinetics of solifenacin succinate suspension versus tablet.

Timeline

Start
2009-09
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Solifenacin Small molecule 10 mg Oral

Indications

No indication recorded.